OGT

In this month’s edition of OGT’s publications in focus, learn about how CytoCell® FISH, SureSeq™ NGS and CytoSure® array products are being used in the latest papers and articles* from our customers and partners in the field. 🔬 “BCR::ABL1-like acute lymphoblastic leukaemia: a single institution experience on identification of potentially therapeutic targetable cases” (This study utilised CytoCell break-apart probes for TCF3::PBX1, CRFL2, JAK2, EPOR, ABL1, ABL2 and, additionally, for IGH and P2RY8 in the CRLF2 rearranged (CRLF2-r) cases) View publication: https://lnkd.in/eRfTzGMa 🔬 “PTPN11 mosaicism causes a spectrum of pigmentary and vascular neurocutaneous disorders and predisposes to melanoma” (Affected skin DNA was sequenced on a targeted next-generation sequencing panel using a SureSeq custom panel of 250 candidate genes of interest) View publication: https://lnkd.in/em9xv8ur 🔬 “17q21.31 microduplication syndrome in a patient with autism spectrum disorder, macrocephaly, and intellectual disability” (During this study aCGH was performed using the CytoSure ISCA 8 × 60K v.2) View publication: https://lnkd.in/e4niCFVU * Providing links to these publications is intended for educational purposes only and does not replace independent professional judgment. Statements of fact and opinions expressed are those of the publications’ authors and, unless expressly stated to the contrary, are not the opinion or position of the Oxford Gene Technology Group (OGT). OGT does not endorse or approve, and assumes no responsibility for, the content, accuracy or completeness of the information presented in these publications.

Sign up for an exclusive seminar on the healthcare journey in AML. Join our parent company, Sysmex Europe Life Science, as they bring you an insightful seminar on Acute Myeloid Leukemia (AML), featuring the distinguished speaker, Prof. Klaus Metzeler, a leading Physician-scientist in the field of haematological malignancies. Don’t miss this opportunity to gain a deeper understanding of the healthcare journey in AML, from diagnosis through treatment and recovery.

Today is World Acute Lymphoblastic Leukaemia Day, and all of us at OGT believe in the importance of spreading awareness about this complex disease. Acute lymphoblastic (or lymphocytic) leukaemia (ALL) is a rapidly progressing cancer that primarily affects children and older adults. Early and accurate diagnosis is vital, as it develops quickly over the course of days or weeks. Below we have provided some key statistics and symptoms of ALL.* Together, we can increase awareness of ALL and work towards a future where every patient has access to the best possible care. To learn more about World Acute Lymphoblastic Leukaemia Day and how you can get involved visit the Know ALL website: https://lnkd.in/eKGuVYVX #WorldALLDay *Statistics and symptoms taken from the American Cancer Society website: https://lnkd.in/eK_d4r_h

At OGT, we’re committed to furthering the understanding of haematological malignancies and our bi-monthly haematological cancer quizzes are a great way to keep your knowledge sharp! This month the focus is on lymphoma, a type of cancer that affects the lymphatic system, a key part of the body's immune system. The lymphatic system includes lymph nodes, lymphatic vessels, the thymus, the spleen, and bone marrow. Ready to put your lymphoma knowledge to the test? Try our quiz: https://lnkd.in/eFdyQTFA #OGTestYourKnowledge #Lymphoma

#ESMO2024 is well underway! If you are here be sure to stop by booth #504, which we are sharing with our parent company Sysmex Europe. Our team of OGT experts will be delighted to have a chat with you about how our haematological range of FISH, array and NGS products can help your lab.

OGT supports World Lymphoma Awareness Day and its mission to raise awareness of lymphoma. Lymphoma is a complex cancer that affects the lymphatic system, developing when white blood cells called lymphocytes grow abnormally and are unable to work properly. There are two primary types of lymphoma: 1. Hodgkin lymphoma 2. Non-Hodgkin lymphoma Sadly, there are still thousands of new cases and disease-related deaths every year. Statistics for 2024 are shown below*. To learn more about World Lymphoma Day and how you can get involved visit the Lymphoma Coalition website: https://lnkd.in/eKZYsRn4 #WorldLymphomaAwarenessDay #WLAD24 #LetsTalkLymphoma *Source: American Cancer Society: https://lnkd.in/e3-qjpiD

Today – 12th September – everyone at OGT would like to voice their support for MPN Awareness Day and its mission to raise awareness about myeloproliferative neoplasms (MPNs). MPNs are a group of rare blood cancers that affect the bone marrow and the production of different blood cells. Early detection and ongoing monitoring is crucial for managing MPNs and improving patient outcomes. For more information about how to get involved in MPN Awareness Day you can visit the Voices of MPN website: https://lnkd.in/eijkyuMC #MPNAwarenessDay #BloodCancerAwarenessMonth

A big thank-you to everyone who came to meet us at Genética 2024 in Brazil 🇧🇷! OGT’s own Dave Bohanna and Graham Halford joined Molecular Biotecnologia to share their FISH expertise with cytogeneticists and clinical scientists from across the country. There were lots of great conversations, and some fantastic speeches from clinicians and academics from around the world! #CytoCell #Genética2024

📢Calling all FISH users📢 At OGT, we are committed to delivering on all your lab's research needs! Your insights are invaluable in shaping the future of scientific innovation and we are here to listen. Today, we’re delving into the topic of FISH probe usage. It is important for you to know how much FISH probe you use to manage costs, ensure accurate diagnostics and avoid delays or shortages in testing processes. #TellOGT

Innovative research using OGT’s CytoCell® FISH, SureSeq™ NGS and CytoSure® array solutions is taking place all over the world 🌎. We’re really proud that, in partnership with our customers, we can be a powerful force for the advancement of genomic medicine. To celebrate this, we’re showcasing a selection of publications* featuring OGT products that have caught our interest over the last month. 🔬 “Cytogenomic characterization of pediatric T-cell acute lymphoblastic leukemia reveals TCR rearrangements as predictive factors for exceptional prognosis” (this study utilised our CytoCell TCRAD Breakapart, TCRB (TRB) Breakapart, TLX3 Breakapart, and TLX1 Breakapart FISH probes) View publication: https://lnkd.in/eMz4BHEE 🔬 “The use of CGH arrays for identifying copy number variations in children with Autism Spectrum Disorder” (the 4 x 180 CytoSure Autism Research Array was used to detect gains or losses in the genome and results were analysed using CytoSure Interpret Software, v.4.10) View publication: https://lnkd.in/e7z7pt3w 🔬 “ZNF217 gene copy number as a marker of response to standard therapy drugs according to ERα status in Breast Cancer” (the ZNF217 gene copy number was evaluated using our CytoCell ZNF217 Amplification probe) View publication: https://lnkd.in/eByK4_9T 🔬 “Combined tumor-based BRCA1/2 and TP53 mutation testing in Ovarian cancer” (BRCA1/2 testing included the use of our SureSeq Ovarian Cancer Panel) https://lnkd.in/ewhagBwP * Providing links to these publications is intended for educational purposes only and does not replace independent professional judgment. Statements of fact and opinions expressed are those of the publications’ authors and, unless expressly stated to the contrary, are not the opinion or position of the Oxford Gene Technology Group (OGT). OGT does not endorse or approve, and assumes no responsibility for, the content, accuracy or completeness of the information presented in these publications.